RATIONALE: α1-Antitrypsin deficiency is one of the most common heritable human diseases, predisposing to liver and lung injury. Significant heterogeneity in phenotypic expression is well documented, but less is known of the prevalence, severity, and correlates of chronic liver disease among individuals presenting with lung disease. OBJECTIVES: To determine the frequency of and risk factors for severe liver fibrosis and cirrhosis among individuals with PiZZ-related lung disease. METHODS: A well-characterized cohort of 57 PiZZ adults attending a tertiary referral respiratory clinic was screened prospectively for clinical, laboratory, radiologic, and (when appropriate) histologic evidence of chronic liver disease. MEASUREMENTS AND MAIN RESULTS: Thirty-six (63.2%) of 57 had a history or clinical findings suggestive of liver disease; or had one or more abnormalities of liver function, or liver ultrasound, and 24 of these underwent liver biopsy. Ten (17.5%) had evidence of severe fibrosis or cirrhosis and were more likely to have higher body mass index (P = 0.04), alanine transaminase (P = 0.0001), alkaline phosphatase (P = 0.0009), prothrombin time (P = 0.0005), and maximal vital capacity (VCmax) (P = 0.04); lower platelet count (P = 0.007); abnormal liver echogenicity (P < 0.001); and splenomegaly (P = 0.001) at ultrasound. Screening with liver ultrasound provided a sensitivity and negative predictive value for severe fibrosis or cirrhosis of 100%, as were the specificity and positive predictive value for platelet count less than or equal to 174,000 per mm(3) and splenomegaly. Among individuals undergoing liver biopsy, fibrosis stage correlated with increasing VCmax (P = 0.02) and % predicted VCmax (P = 0.05), and decreasing residual volume/total lung capacity (TLC) (P = 0.02) and % predicted residual volume/TLC (P = 0.05). CONCLUSIONS: Significant chronic liver disease is common in PiZZ individuals with lung disease and can be screened effectively by a combination of conventional tests of liver function, platelet count, and liver ultrasound.
RATIONALE: α1-Antitrypsin deficiency is one of the most common heritable human diseases, predisposing to liver and lung injury. Significant heterogeneity in phenotypic expression is well documented, but less is known of the prevalence, severity, and correlates of chronic liver disease among individuals presenting with lung disease. OBJECTIVES: To determine the frequency of and risk factors for severe liver fibrosis and cirrhosis among individuals with PiZZ-related lung disease. METHODS: A well-characterized cohort of 57 PiZZ adults attending a tertiary referral respiratory clinic was screened prospectively for clinical, laboratory, radiologic, and (when appropriate) histologic evidence of chronic liver disease. MEASUREMENTS AND MAIN RESULTS: Thirty-six (63.2%) of 57 had a history or clinical findings suggestive of liver disease; or had one or more abnormalities of liver function, or liver ultrasound, and 24 of these underwent liver biopsy. Ten (17.5%) had evidence of severe fibrosis or cirrhosis and were more likely to have higher body mass index (P = 0.04), alanine transaminase (P = 0.0001), alkaline phosphatase (P = 0.0009), prothrombin time (P = 0.0005), and maximal vital capacity (VCmax) (P = 0.04); lower platelet count (P = 0.007); abnormal liver echogenicity (P < 0.001); and splenomegaly (P = 0.001) at ultrasound. Screening with liver ultrasound provided a sensitivity and negative predictive value for severe fibrosis or cirrhosis of 100%, as were the specificity and positive predictive value for platelet count less than or equal to 174,000 per mm(3) and splenomegaly. Among individuals undergoing liver biopsy, fibrosis stage correlated with increasing VCmax (P = 0.02) and % predicted VCmax (P = 0.05), and decreasing residual volume/total lung capacity (TLC) (P = 0.02) and % predicted residual volume/TLC (P = 0.05). CONCLUSIONS: Significant chronic liver disease is common in PiZZ individuals with lung disease and can be screened effectively by a combination of conventional tests of liver function, platelet count, and liver ultrasound.
Authors: Robert A Sandhaus; Gerard Turino; Mark L Brantly; Michael Campos; Carroll E Cross; Kenneth Goodman; D Kyle Hogarth; Shandra L Knight; James M Stocks; James K Stoller; Charlie Strange; Jeffrey Teckman Journal: Chronic Obstr Pulm Dis Date: 2016-06-06
Authors: Christine I Wooddell; Keith Blomenkamp; Ryan M Peterson; Vladimir M Subbotin; Christian Schwabe; James Hamilton; Qili Chu; Dawn R Christianson; Julia O Hegge; John Kolbe; Holly L Hamilton; Maria F Branca-Afrazi; Bruce D Given; David L Lewis; Edward Gane; Steven B Kanner; Jeffrey H Teckman Journal: JCI Insight Date: 2020-06-18
Authors: Marianna Mela; Wendy Smeeton; Susan E Davies; Elena Miranda; Cinzia Scarpini; Nick Coleman; Graeme J M Alexander Journal: Chronic Obstr Pulm Dis Date: 2020-07
Authors: Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak Journal: PLoS One Date: 2015-10-29 Impact factor: 3.240
Authors: Florie Borel; Qiushi Tang; Gwladys Gernoux; Cynthia Greer; Ziqiong Wang; Adi Barzel; Mark A Kay; Leonard D Shultz; Dale L Greiner; Terence R Flotte; Michael A Brehm; Christian Mueller Journal: Mol Ther Date: 2017-09-25 Impact factor: 11.454
Authors: Mattias Mandorfer; Theresa Bucsics; Veronika Hutya; Karin Schmid-Scherzer; Benedikt Schaefer; Heinz Zoller; Arnulf Ferlitsch; Markus Peck-Radosavljevic; Michael Trauner; Peter Ferenci; Meinhard Kneussl; Thomas Reiberger Journal: United European Gastroenterol J Date: 2018-02-28 Impact factor: 4.623
Authors: Elizabeth Rodríguez-Romero; Juan Antonio Suárez-Cuenca; César Iván Elizalde-Barrera; Paul Mondragón-Terán; José Enrique Martínez-Hernández; Eduardo Gómez-Cortés; Rebeca Pérez-Cabeza de Vaca; Rolando E Hernández-Muñoz; Alberto Melchor-López; Nayeli Gabriela Jiménez-Saab Journal: Med Sci Monit Date: 2015-04-27